Mirabegron

Drug Profile

Mirabegron

Alternative Names: Betanis; Betmiga; Myrbetriq; YM-178

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Johns Hopkins University
  • Class Acetamides; Ethanolamines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase III Interstitial cystitis
  • Phase I/II Erectile dysfunction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Overactive bladder(In adolescents, In children) in Germany (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Overactive bladder(In adolescents, In children) in Japan (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Overactive bladder(In adolescents, In children) in Norway (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top